A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C

Trial Profile

A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2014

At a glance

  • Drugs Valopicitabine (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Idenix Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2008 Status changed from in progress to discontinued as reported by Idenix.
    • 30 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top